This result is consistent with those of previous studies demonstrating that TP53 mutations occur in 30–40% of patients with HBV-associated HCC, compared to 20% of patients with HCV-associated HCC (30, 31). This evidence concerns the gene TP53 and hepatocellular carcinoma.